文献速递消化道肿瘤放疗

食管癌放疗剂量递增再探讨:2004至2012年美国国家癌症数据库分析

Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-08-23

该研究基于美国国家癌症数据库2004至2012年数据,纳入6854例接受根治性同步放化疗、放疗剂量≥50 Gy且未手术的I至III期食管癌患者,比较50至50.4 Gy与>50.4 Gy的总体生存(OS)。结果显示剂量递增>50.4 Gy未改善OS,亚组和倾向性评分匹配分析均无显著差异,与INT-0123试验结果一致。

要点

  • 根治性同步放化疗的I至III期食管癌中,放疗剂量>50.4 Gy未改善总体生存。
  • 按50至50.4、51至54、55至60、>60 Gy分组及组织学类型亚组分析均未见OS获益。
  • 多变量分析中女性、较低Charlson-Deyo评分、私人保险、颈段/上段食管、鳞癌、较低T分期和N0与OS改善相关。

核心结论

  • 在大型国家队列中,I至III期食管癌接受根治性同步放化疗时,剂量递增>50.4 Gy未带来OS改善。
  • 结果与INT-0123试验一致,提示尽管采用先进放疗技术,>50.4 Gy的剂量递增仍未改变OS。

研究设计与样本

  • 回顾性队列研究,数据来自美国国家癌症数据库2004至2012年。
  • 纳入6854例I至III期食管癌患者,均接受同步放化疗、放疗剂量≥50 Gy且未手术。
  • 采用Cox比例风险回归和倾向性评分匹配比较OS。

主要发现

  • 3821例(55.7%)接受50至50.4 Gy,3033例(44.3%)接受>50.4 Gy。
  • 单变量分析显示50至50.4 Gy与>50.4 Gy组OS无显著差异(P=.53)。
  • 按50至50.4、51至54、55至60、>60 Gy分组,各组OS与50至50.4 Gy相比均无显著差异。
  • 按组织学类型和调强放疗(IMRT)亚组分析均未见剂量递增获益,倾向性评分匹配证实无统计学显著差异。
  • 多变量分析中与OS改善相关的因素包括女性、较低Charlson-Deyo评分、私人保险、颈段/上段食管、鳞癌、较低T分期和N0(所有分析P<.01)。

关键数值与推荐

  • 纳入患者放疗剂量≥50 Gy,比较组为50至50.4 Gy与>50.4 Gy。
  • 剂量分组界值为50至50.4、51至54、55至60和>60 Gy。
  • 多变量分析中所有与OS改善相关因素的P值均<.01。

临床怎么用

  • 对于I至III期食管癌接受根治性同步放化疗的患者,不应常规将放疗剂量递增至>50.4 Gy以追求OS获益。
  • 局部控制未在本研究中评估,剂量递增对局部控制的潜在获益需另行考量。
  • 改善食管癌OS可能需要新的治疗策略。

局限性

  • 本研究未评估局部控制。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effect of radiation dose escalation on overall survival (OS) for patients with nonmetastatic esophageal cancer treated with concurrent radiation and chemotherapy. METHODS AND MATERIALS: Patients diagnosed with stage I to III esophageal cancer treated from 2004 to 2012 were identified from the National Cancer Data Base. Patients who received concurrent radiation and chemotherapy with radiation doses of ≥50 Gy and did not undergo surgery were included. OS was compared using Cox proportional hazards regression and propensity score matching. RESULTS: A total of 6854 patients were included; 3821 (55.7%) received 50 to 50.4 Gy and 3033 (44.3%) received doses >50.4 Gy. Univariate analysis revealed no significant difference in OS between patients receiving 50 to 50.4 Gy and those receiving >50.4 Gy (P=.53). The dose analysis, binned as 50 to 50.4, 51 to 54, 55 to 60, and >60 Gy, revealed no appreciable difference in OS within any group compared with 50 to 50.4 Gy. Subgroup analyses investigating the effect of dose escalation by histologic type and in the setting of intensity modulated radiation therapy also failed to reveal a benefit. Propensity score matching confirmed the absence of a statistically significant difference in OS among the dose levels. The factors associated with improved OS on multivariable analysis included female sex, lower Charlson-Deyo comorbidity score, private insurance, cervical/upper esophagus location, squamous cell histologic type, lower T stage, and node-negative status (P<.01 for all analyses). CONCLUSIONS: In this large national cohort, dose escalation >50.4 Gy did not result in improved OS among patients with stage I to III esophageal cancer treated with definitive concurrent radiation and chemotherapy. These data suggest that despite advanced contemporary treatment techniques, OS for patients with esophageal cancer remains unaltered by escalation of radiation dose >50.4 Gy, consistent with the results of the INT-0123 trial. Furthermore, these data highlight that many radiation oncologists have not embraced the concept that dose escalation does not improve OS. Although local control, not investigated in the present study, might benefit from dose escalation, novel therapies are needed to improve the OS of patients with esophageal cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Brower JV, Chen S, Bassetti MF, et al. Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. Int J Radiat Oncol Biol Phys. 2016. PMID: 27869098. doi:10.1016/j.ijrobp.2016.08.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。